ATE524472T1 - SUBSTITUTED PYRIMIDODIAZEPINES SUBSTITUTED AS PLK1 INHIBITORS - Google Patents

SUBSTITUTED PYRIMIDODIAZEPINES SUBSTITUTED AS PLK1 INHIBITORS

Info

Publication number
ATE524472T1
ATE524472T1 AT08717594T AT08717594T ATE524472T1 AT E524472 T1 ATE524472 T1 AT E524472T1 AT 08717594 T AT08717594 T AT 08717594T AT 08717594 T AT08717594 T AT 08717594T AT E524472 T1 ATE524472 T1 AT E524472T1
Authority
AT
Austria
Prior art keywords
substituted
pyrimidodiazepines
plk1 inhibitors
plk1
inhibitors
Prior art date
Application number
AT08717594T
Other languages
German (de)
Inventor
Jianping Cai
Shaoqing Chen
Xin-Jie Chu
Kang Le
Kin-Chun Thomas Luk
Peter Michael Wovkulich
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE524472(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE524472T1 publication Critical patent/ATE524472T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AT08717594T 2007-03-22 2008-03-11 SUBSTITUTED PYRIMIDODIAZEPINES SUBSTITUTED AS PLK1 INHIBITORS ATE524472T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22
PCT/EP2008/052847 WO2008113711A1 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as plk1 inhibitors

Publications (1)

Publication Number Publication Date
ATE524472T1 true ATE524472T1 (en) 2011-09-15

Family

ID=39415299

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08717594T ATE524472T1 (en) 2007-03-22 2008-03-11 SUBSTITUTED PYRIMIDODIAZEPINES SUBSTITUTED AS PLK1 INHIBITORS

Country Status (24)

Country Link
US (1) US7517873B2 (en)
EP (1) EP2139892B1 (en)
JP (1) JP5087640B2 (en)
KR (1) KR101157848B1 (en)
CN (2) CN102746175B (en)
AR (1) AR065794A1 (en)
AT (1) ATE524472T1 (en)
AU (1) AU2008228303B2 (en)
BR (1) BRPI0809088A2 (en)
CA (1) CA2680757A1 (en)
CL (1) CL2008000785A1 (en)
CY (1) CY1112102T1 (en)
DK (1) DK2139892T3 (en)
ES (1) ES2371832T3 (en)
HK (1) HK1139936A1 (en)
HR (1) HRP20110807T1 (en)
IL (1) IL200617A (en)
MX (1) MX2009010034A (en)
PE (1) PE20120495A1 (en)
PL (1) PL2139892T3 (en)
PT (1) PT2139892E (en)
SI (1) SI2139892T1 (en)
TW (1) TWI363629B (en)
WO (1) WO2008113711A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023269A2 (en) * 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5h-pyrimido [4, 5-b[1, 4] diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
GEP20125704B (en) 2007-09-25 2012-12-10 Takeda Pharmaceuticals Co Plk kinase inhibitors
ES2585110T3 (en) * 2007-09-28 2016-10-03 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
WO2009067547A1 (en) * 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (en) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 Benzene or thiophene derivative and use thereof as vap-1 inhibitor
JP2011527667A (en) * 2008-06-18 2011-11-04 武田薬品工業株式会社 Halo-substituted pyrimidodiazepine
TWI432436B (en) 2008-12-09 2014-04-01 Gilead Sciences Inc Modulators of toll-like receptors
JP5908728B2 (en) * 2009-01-06 2016-04-26 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Pyrimido-diazepinone kinase skeletal compounds and methods of treating diseases
KR101702609B1 (en) 2009-06-17 2017-02-03 버텍스 파마슈티칼스 인코포레이티드 Inhibitors of influenza viruses replication
EP2477987B1 (en) 2009-09-14 2018-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (en) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед INFLUENCES OF INFLUENZA VIRUS REPLICATION
EP3388436B1 (en) 2013-03-15 2020-08-12 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
KR20160034379A (en) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. Inhibitors of transcription factors and uses thereof
TWI652014B (en) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 Heterocyclic substituted bicycloazole insecticide
RU2019104421A (en) 2013-11-13 2019-04-17 Вертекс Фармасьютикалз Инкорпорейтед METHODS OF OBTAINING ANTIBODY VIRUS REPLICATION INHIBITORS
NZ719729A (en) 2013-11-13 2022-04-29 Vertex Pharma Inhibitors of influenza viruses replication
EP3099693A4 (en) * 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
EP3166607B1 (en) 2014-07-11 2022-08-31 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
CN106715437A (en) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 Diazepane derivatives and uses thereof
EA201790369A1 (en) 2014-09-16 2017-10-31 Джилид Сайэнс, Инк. SOLID FORMS OF THOUGH-RECEPTOR MODULATOR
SG11201701472VA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Methods of preparing toll-like receptor modulators
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017044849A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
PE20181086A1 (en) 2015-09-11 2018-07-05 Dana Farber Cancer Inst Inc ACETAMIDE HAVE THRIZOLODIAZEPINES AND USES OF THE SAME
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
CN109311901A (en) * 2016-04-07 2019-02-05 达纳-法伯癌症研究所有限公司 The method for the lesion that pyrimido-diazepine ketone kinases framework compound and treatment PI3K are mediated
US20220378919A1 (en) * 2019-09-27 2022-12-01 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases
KR102313753B1 (en) * 2020-03-27 2021-10-19 (주) 업테라 Vanillin derivative compounds inducing selective degradation of PLK1
WO2022145989A1 (en) * 2020-12-31 2022-07-07 (주) 업테라 Pyrimidodiazepine derivative as selective plk1 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL354241A1 (en) 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
UA76512C2 (en) 2001-09-04 2006-08-15 Boehringer Ingelheim Pharma Dihydropteridinones, a method for producing thereof and use thereof as medicament
JP5243970B2 (en) * 2006-02-14 2013-07-24 バーテックス ファーマシューティカルズ インコーポレイテッド Dihydrodiazepines useful as inhibitors of protein kinases
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
AR065794A1 (en) 2009-07-01
CA2680757A1 (en) 2008-09-25
CY1112102T1 (en) 2015-11-04
CN102746175A (en) 2012-10-24
CL2008000785A1 (en) 2009-03-27
TW200843781A (en) 2008-11-16
WO2008113711A1 (en) 2008-09-25
HRP20110807T1 (en) 2011-12-31
CN101636399A (en) 2010-01-27
EP2139892A1 (en) 2010-01-06
PE20120495A1 (en) 2012-05-12
US20080234255A1 (en) 2008-09-25
US7517873B2 (en) 2009-04-14
IL200617A (en) 2014-02-27
KR101157848B1 (en) 2012-07-11
TWI363629B (en) 2012-05-11
PL2139892T3 (en) 2012-03-30
AU2008228303B2 (en) 2012-04-19
DK2139892T3 (en) 2011-12-12
ES2371832T3 (en) 2012-01-10
CN101636399B (en) 2012-04-18
AU2008228303A1 (en) 2008-09-25
JP5087640B2 (en) 2012-12-05
HK1139936A1 (en) 2010-09-30
MX2009010034A (en) 2009-10-12
JP2010521514A (en) 2010-06-24
CN102746175B (en) 2014-01-15
EP2139892B1 (en) 2011-09-14
SI2139892T1 (en) 2011-12-30
BRPI0809088A2 (en) 2014-09-09
KR20090119913A (en) 2009-11-20
PT2139892E (en) 2011-11-21
IL200617A0 (en) 2010-05-17

Similar Documents

Publication Publication Date Title
ATE524472T1 (en) SUBSTITUTED PYRIMIDODIAZEPINES SUBSTITUTED AS PLK1 INHIBITORS
CY2020024I2 (en) BETA-LACTAMAS INHIBITORS
CY2017016I1 (en) PROTEASOMY INHIBITORS
ATE522535T1 (en) PYRROLOTRIAZINE KINASE INHIBITORS
DK2185567T3 (en) Substituted bicyclolactam compounds
DK2288375T3 (en) PEGYLED INSULIN-LISPRO COMPOUNDS
BRPI0920707A2 (en) compounds
BRPI0813500A2 (en) ANTIVIAL COMPOUNDS
DK2242759T3 (en) compounds
BRPI0821086A2 (en) INSECTICATED COMPOUNDS
BRPI0811264A2 (en) COMPOUNDS
BRPI0922880A2 (en) kinase inhibitor compounds
DK2323972T3 (en) C7-FLUOR-SUBSTITUTED TETRACYLIN COMPOUNDS
DK2297162T3 (en) compounds
BRPI0918564A2 (en) inhibitors
BRPI0907122A2 (en) Substituted pyridoindoles (1-azinone)
BRPI0814424A2 (en) HYPEROCYCLE COMPOUNDS
UY3776Q (en) WRISTWATCH
BRPI0916432A2 (en) compounds
BRPI0809996A2 (en) COMPOUNDS
BRPI0815181A2 (en) COMPOUNDS
DE112008002921A5 (en) chuck
DK2206698T3 (en) Ethynylindole compounds
BRPI0922152A2 (en) Compounds
BRPI0814613A2 (en) COMPOUNDS

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2139892

Country of ref document: EP